Drugs /

dextromethorphan

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.

Clinical Trials

View Clinical Trials for dextromethorphan

Dextromethorphan has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating dextromethorphan, 2 are phase 1 (2 open).

BRAF V600E and BRAF V600K are the most frequent biomarker inclusion criteria for dextromethorphan clinical trials.

Malignant solid tumor is the most common disease being investigated in dextromethorphan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dextromethorphan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dextromethorphan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dextromethorphanum, morphinan, 3-methoxy-17-methyl-, (9alpha,13alpha,14alpha)-, delta-methorphan, dextromethorphan [chemical/ingredient], d-methorphan, (+)-dextromethorphan, dextrometorfano, d-methorphan, methorphan d, dxm, dextromethorphan (substance), dextromethorphan, dextromethmorphan, dextromethorfan, dextromethorphan, dm, dextrométhorphane, dex, dextromethorphan (product)
NCIT ID [1]:
C62022
SNOMED ID [1]:
F-61C91

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.